Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6β-hydroxycortisol

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 33-43

  Ushiama, Hideki ^a,b   Echizen, Hirotoshi ^a,b   Nachi, Shinobu ^a,b   Ohnishi, Akihiro ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 3A; DRUG METABOLITE; HYDROCORTISONE; LANSOPRAZOLE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; ENZYME INHIBITION; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; URINALYSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROCORTISONE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OMEPRAZOLE; OXIDOREDUCTASES, N-DEMETHYLATING; PENICILLINS; PROTEIN SYNTHESIS INHIBITORS;

EID: 0036331529     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.125559     Document Type: Article

References (32)

1. Peptic ulcer and Helicobacter pylori
2. Helicobacter pylori infection and the development of gastric cancer
3. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin
4. Comparison of efficacy of 400 mg and 800 mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population
5. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: A randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens
6. Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP)3A4: An update focused on clarithromycin, azithromycin and dirithromycin
7. Cytochrome P450 3A4: Regulation and role in drug metabolism
8. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
9. Effect of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
10. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin
11. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
12. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones
13. Activities of β-lactams and macrolides against Helicobacter pylori
14. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction
15. The urinary 6β-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase
16. A single dose of methadone inhibits cytochrome P450 3A in healthy volunteers as assessed by the urinary cortisol ratio
17. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
18. Fluconazole: A potent inhibitor of cytochrome P-450-dependent drug metabolism in mice and human in vivo - Comparative study with ketoconazole
19. Impairment of CYP3A4 capacity in patients receiving danazol therapy: Examination on oxidative cortisol metabolism
20. Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors
21. Polymorphism drug oxidation: Pharmacokinetic basis and comparison of experimental indices
22. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in human
23. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine
24. 13C-aminopyrine breath test: Comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens
25. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine
26. Oxidative metabolism of clarithromycin in the presence of human liver microsomes: Major role for the cytochrome P4503A (CYP3A) subfamily
27. In vivo effect of clarithromycin on multiple cytochrome P450s
28. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
29. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
30. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state
31. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
32. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status